Thailand Regulatory Application for Remplir™

Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device Remplir™, with clearance expected in Q3 CY2025.

This is an important milestone in our global expansion plans for Remplir™, with the Thailand nerve repair market representing an $84M opportunity.

Remplir is now gaining record sales traction in Australia, New Zealand and Singapore, with all sights set on US FDA clearance in March/April 2025.

Click to read the ASX Release.